

Table 1. Editors and Peer Reviewers of Cochrane Groups With Competing Interests

#	Editor / Peer-reviewer	Cochrane Group	Financial relationship with companies that make anticoagulants
1	Philip Bath, MD*	Stroke	He is Professor of Stroke Medicine at The University of Nottingham, a post supported by The Stroke Association. Sponsors of the UK Stroke Association include Astra Zeneca, Boehringer Ingleheim, Bristol Myers Squibb, Merck Sharp Dohme, Sanofi-Synthelabo, and Pfizer. He has received payment for talks given at commercially funded symposia (involving several companies). He has received payment acting as a consultant to several companies. ^{1,2}
2	Dániel Bereczki, MD	Stroke	He was co-investigator in RCTs sponsored by Glaxo, Astra, UCB, Sanofi-Synthelabo, and Richter. He accepted unrestricted research support from several pharmaceutical companies (Sanofi-Synthelabo, Richter, Aventis, UCB, Glaxo, Pfizer), and his participation at several scientific meetings was partly supported by pharmaceutical companies. Travel costs to participate at a Cochrane Reviewers' Training Course were covered by a pharmaceutical company (Richter). ¹
3	Eivind Berge, MD*	Stroke	He has received travel support to conferences and meetings and honoraria for lessons at meetings from various pharmaceutical companies. He has received unconditional grants from Nycomed Pharma, Pharmacia, Upjohn, and AstraZeneca for coordinating the Heparin in Acute Embolic Stroke Trial. ^{1,3}
4	David Bergqvist, MD*	Peripheral Vascular Disease	He participated on advisory boards and/or research steering committees for AstraZeneca, Aventis, Boehringer Ingelheim, Pharmacia/Pfizer, and Sanofi-Synthelabo ⁴
5	Julia	Peripheral	She participated in trials of clopidogrel (Plavix) funded by Sanofi

	Brittenden, MD*	Vascular Disease	Synthelabo. ⁵⁻⁷
6	Livia Candelise, MD	Stroke	She coordinates the Cochrane Neurological Network (CNN). Until 2005, the CNN received support from pharmaceutical companies. ¹
7	Graeme Hankey, MD	Stroke	He has received honoraria, travel and research support from several pharmaceutical companies during the past 10 years. The honoraria have been for speaking at symposia at scientific meetings, and for giving advice on advisory boards. ¹
8	Bill Hiatt, MD*	Peripheral Vascular Disease	He served as a consultant to and received speakers' bureau honoraria from the Bristol Myers Squibb/Sanofi-Synthelabo Partnership. ^{8 9}
9	Peter Langhorne, MD	Stroke	He has received funding to present at conferences and educational grants from pharmaceutical firms. ¹
10	Saskia Middeldorp, MD*	Peripheral Vascular Disease	As one of the Matisse investigators, she investigated fondaparinux supported by a grant from NV Organon and Sanofi-Synthelabo. ¹⁰
11	Martin Prins, MD*	Peripheral Vascular Disease	He participated on the steering committees and in obtaining funding from Santofi-Synthelabo and NV Organon drug companies for trials of fondaparinux (Aristra) in treatment of DVT and PE. ^{10, 11} Based on the results of these 2 studies, the FDA approved fondaparinux for the treatment of DVT and PE on May 28, 2004. Anticipating this approval, Sanofi-Synthelabo sold Aristra and nadroparine (Fraxiparine) on April 13, 2004 to GlaxoSmithKline for about \$360 million. ¹² AstraZeneca LP; Aventis Pharmaceuticals; Bristol-Myers Squibb/Sanofi-Syntholabo Partnership; GlaxoSmithKline; Organon; and Sanofi-Synthelabo LLC supported his review of Antithrombotic Therapy for Venous

			Thromboembolic Disease for the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. ¹³ Sanofi Winthrop provided him with research funding for a study comparing Fraxiparine with heparin. ¹⁴
12	Peter P. Sandercock, MD*	Stroke	He was the principal investigator of the International Stroke Trial (IST). Its sponsors include the UK Stroke Foundation which is funded by Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers-Squibb, Sanofi-Synthelabo, Merck Sharp Dohme, and Pfizer. ^{2, 15} He has received lecture fees and travel expenses for lectures delivered at conference from a variety of manufacturers of antiplatelet and anticoagulant drugs (Sanofi, Bristol Myers Squibb, Sanofi-Synthelabo, Organon, Boehringer Ingelheim, Janssen). He has received research grants from Glaxo-Wellcome and Boehringer Ingelheim including the drug supply for the start-up phase of the IST-3 trial. ¹⁶
13	Thomas Wakefield, MD*	Peripheral Vascular Disease	As one of the "PIOPED" investigators, he co-authored, "Multidetector Computed Tomography for Acute Pulmonary Embolism," funded by the US National Institutes of Health. ¹⁷ One of his research studies, "Inhibition of Deep Vein Thrombosis (DVT)-Induced Inflammation and Thrombosis by Melagatron," is funded by Astra Zeneca. ¹⁸ He has been an author on a study of the "American Venous Forum" that is funded by Sanofi Aventis. ¹⁹ At the University of Michigan Medical Center, he has an endowed chair as Professor of Surgery in the Section of Vascular Surgery and directs the noninvasive vascular laboratory. The need for the tests that this laboratory performs for clinical and research purposes depends on the assumption that anticoagulant prophylaxis and therapy is indicated for venous thromboembolism.

* Undisclosed financial conflict of interest

Table 2. Authors of Cochrane Anticoagulation Reviews With Competing Interests

#	Reviewer	# review	Financial conflict of interest
1	Ale Algra, MD*	33	He was a member of the Executive Committee of the European / Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), funded by the Netherlands Heart Foundation, University Medical Center Utrecht, UK Stroke Association, French Ministry of Health, Janivo Foundation, Aegon, Netherlands Thrombosis Foundation, and the European Commission. ²⁰ The UK Stroke Association's sponsors include Boehringer Ingelheim, Sanofi-Synthelabo, Bristol Myers Squibb, Pfizer, Merck Sharp Dohme, and Astra Zeneca. ² A secondary analysis of ESPRIT data was funded by Boehringer Ingelheim. ²¹
2	Eivind Berge	Author: 14 Editor: 1, 13, 15-17, 23, 24, 32, 33, 43, 47, 52	See editors (Table 2).
3	Harry R. Büller, MD*	2, 5, 6, 20	He received honoraria and grants from Sanofi-Synthelabo, NV Organon ¹¹ and research funding from Leo Laboratories for a comparison of tinzaparin and enoxaparin. ²² AstraZeneca LP; Aventis Pharmaceuticals; Bristol-Myers Squibb/Sanofi-Synthelabo Partnership; GlaxoSmithKline; NV Organon Sanofi-Synthelabo LLC supported his review of Antithrombotic Therapy for Venous Thromboembolic Disease for the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. ¹³
4	I. Chung,	18, 19	He was a co-investigator in the "Warfarin and Antiplatelet

	MD*		Therapy in Heart Failure (WATCH) Trial” which was partly funded by Dupont, Sanofi and Bristol-Myers Squibb. ²³
5	Alexander T Cohen, MD*	10	As a member of the PEGASUS investigators and ARTEMIS investigators, he conducted fondaparinux trials funded by NV Organon Sanofi-Synthelabo and GlaxoSmithKline and has been a consultant for these anticoagulant producing companies. ^{24, 25}
6	Sergio Coccheri, MD*	21	He served as one of the CAPRIE investigators in a trial funded by Sanofi and Bristol-Myers Squibb. ²⁶
7	Benilde Cosmi, MD	21, 50	He received lecture fees from Instrumentation Laboratory in Milan regarding anticoagulation studies. ²⁷
8	Carl Counsell, MD*	13, 15, 16, 17	He was on the Steering Committee of the International Stroke Trial. ¹⁶ Its sponsors include the UK Stroke Foundation, which is funded by Astra Zeneca, Boehringer, Bristol-Myers-Squibb, Ingleheim, Sanofi-Synthelabo, Merck Sharp Dohme, and Pfizer. ^{2, 15}
9	S.F.T.M. de Bruijn, MD*	1	He was co-principal investigator for the cerebral venous sinus thrombosis (CVST) Study Group Trial. Sanofi-Winthrop (Dutch division) funded the trial. ²⁸
10	E.L.L.M. De Schryver, MD*	33	He/she was a member of the Executive Committee of the European / Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), funded by the Netherlands Heart Foundation, University Medical Center Utrecht, UK Stroke Association, French Ministry of Health, Janivo Foundation, Aegon, Netherlands Thrombosis Foundation, and the European Commission. ²⁰ The UK Stroke Association’s

			sponsors include Boehringer Ingelheim, Sanofi-Synthelabo, Bristol Myers Squibb, Pfizer, Merck Sharp Dohme, and Astra Zeneca. ² A secondary analysis of ESPRIT data was funded by Boehringer Ingelheim. ²¹
11	James D. Douketis, MD*	11	He is a research scholar of the Heart and Stroke Foundation of Canada. Funders of this foundation include AstraZeneca Canada, Bayer, Boehringer Ingelheim Ltd./Ltée, Sanofi-Aventis, and Pfizer Canada Inc. ²⁹
12	John W. Eikelboom, MD*	11	He is a research scholar of the Heart and Stroke Foundation of Canada. Funders of this foundation include AstraZeneca Canada, Bayer, Boehringer Ingelheim Ltd./Ltée, Sanofi-Aventis, and Pfizer Canada Inc. ²⁹ He has received honoraria for speaking at symposia sponsored by pharmaceutical companies that market low-molecular-weight heparin preparations, ³⁰ including Aventis, Sanofi-Synthelabo and grants from Aventis and Sanofi-Synthelabo. ³¹
13	DC Felmeden, MD	54	He/she worked in the Haemostasis, Thrombosis and Vascular Biology Unit, University of Birmingham. This unit undertakes clinical trials of antithrombotic therapy in cardiovascular disease and stroke, and has received research funding from various pharmaceutical companies involved in thrombosis and antithrombotic therapy.
14	Gord Gubitz, MD*	15, 17	He enrolled several patients in the International Stroke Trial. Its sponsors include the UK Stroke Foundation which is funded by Astra Zeneca, Boehringer, Bristol-Myers-Squibb, Ingelheim, Sanofi-Synthelabo, Merck Sharp Dohme, and Pfizer. ^{2, 15}
15	Robert G.	32, 43	He co-authored an article supporting anticoagulant use in

	Hart, MD*		atrial fibrillation patients funded by the American Heart Association. AHA financial supporters include Abbott Vascular, AstraZeneca, Bayer, Bayer HealthCare, Boehringer Ingelheim Ltd./Ltée, Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Inc., Merck/Schering Plough, Novartis Pharmaceuticals Corporation, Pfizer Pharmaceuticals, Sanofi-Aventis, Sanofi-Synthelabo Inc., Schering Plough, and Wyeth. ^{32, 33} Dr Hart was a leader of the ACTIVE W trial, comparing vitamin k inhibitors with antiplatelet agents, funded by Sanofi -Aventis and Bristol-Myers Squibb. ³⁴
16	L.Jaap Kappelle, MD, PhD*	33	He was a member of the Executive Committee of the European / Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), funded by the Netherlands Heart Foundation, University Medical Center Utrecht, UK Stroke Association, French Ministry of Health, Janivo Foundation, Aegon, Netherlands Thrombosis Foundation, and the European Commission. ²⁰ The UK Stroke Association's sponsors include Boehringer Ingleheim, Sanofi-Synthelabo, Bristol Myers Squibb, Pfizer, Merck Sharp Dohme, and Astra Zeneca. ² A secondary analysis of ESPRIT data was funded by Boehringer Ingleheim. ²¹
17	Marianne Koopman, MD*	5, 6, 20, 37	She has been paid by Sanofi Winthrop (Paris) for a trial involving fraxiparine, a LMWH. ¹⁴
18	Peter J. Koudstaal, MD*	23, 24, 33	He was the principal investigator of the European / Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), funded by the Netherlands Heart Foundation,

			<p>University Medical Center Utrecht, UK Stroke Association, French Ministry of Health, Janivo Foundation, Aegon, Netherlands Thrombosis Foundation, and the European Commission.²⁰ The UK Stroke Association's sponsors include Boehringer Ingelheim, Sanofi-Synthelabo, Bristol Myers Squibb, Pfizer, Merck Sharp Dohme, and AstraZeneca.² A secondary analysis of ESPRIT data was funded by Boehringer Ingelheim.²¹</p>
19	<p>Anthonie W.A. Lensing, MD*</p>	3, 4	<p>He is an employee of NV Organon.¹⁰ Sanofi-Synthelabo and NV Organon sold fondaparinux and fraxiparine to GlaxoSmithKline in 2004 for \$360 million.¹² He had anticoagulant research funding from Sanofi Winthrop for a study of nadroparine³⁵ and Leo Laboratories for a comparison of tinzaparin and enoxaparin.²²</p>
20	<p>Gregory Y.H. Lip, MD*</p>	18, 19	<p>AstraZeneca LP; Aventis Pharmaceuticals; Bristol-Myers Squibb/Sanofi-Syntholabo Partnership; GlaxoSmithKline; Organon Sanofi-Synthelabo LLC supported his review of Antithrombotic Therapy in Peripheral Arterial Occlusive Disease for the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.¹³ Bristol-Myers-Squibb funded one of his trials.³⁶ As one of the CORTES Investigators, he was funded by Knoll/Abbott Laboratories to study reviparin (Clivarin-a low molecular weight heparin).³⁷ Dr. Lip has received research funding from AstraZeneca, Merck, and Servier, and has received honoraria for his participation on advisory boards and/or as a speaker at educational events from AstraZeneca, Servier, Boehringer Ingelheim, Novartis, Mitsubishi, Pharma,</p>

			Yamanuchi, Bristol-Myers Squibb, Sanofi-Synthelabo-Organon, GlaxoSmithKline, Sankyo, and Merck. ⁴ His unit was a centre for “The Warfarin and Antiplatelet Therapy in Heart Failure (WATCH) Trial,” funded by Dupont, Sanofi and Bristol-Myers Squibb. ²³
21	Kirk D. Magee, MD	29, 30, 31	His employer, the Division of Emergency Medicine, University of Alberta, received funding from Pharmacia, Aventis, and Sanofi for educational and research purposes. ³⁸
22	Saskia Middeldorp, MD*	Author: 34, Editor: 2-8, 10-12, 20, 21, 25, 28, 37-42, 59	See editors above.
23	David Moher, PhD	29, 30	His employer, the Division of Emergency Medicine, University of Alberta, received funding from Pharmacia, Aventis, and Sanofi for educational and research purposes. ³⁸
24	Martin H. Prins, MD*	Author: 2, 3, 4, 5, 6, 7, 8, 20 Editor: 10-12, 21, 25, 28, 37-42, 59	See editor list above.
25	Daniel John Quinlan, MD*	11	He has received funding from Knoll Pharmaceuticals, ³⁷ and honoraria for speaking at symposia sponsored by pharmaceutical companies that market low-molecular-weight heparin preparations, ³⁰ including Aventis and Sanofi-Synthelabo. ³¹
26	Morten Schnack Rasmussen,	28	During the review process, he was part time working as a research fellow on long term thrombosis prophylaxis, partly paid for by Pharmacia/Upjohn. ³⁹ He was also principle

	MD*		investigator for a Pfizer-funded dalteparin prophylaxis trial. ⁴⁰
27	Brian H. Rowe, MD	29, 30	His employer, the Division of Emergency Medicine, University of Alberta, received funding from Pharmacia, Aventis, and Sanofi for educational and research purposes. ³⁸
28	Peter P. Sandercock, MD*	Author: 13 – 17 Editor: 1, 23, 24, 32, 33, 43, 47, 52	See editors (Table 2).
29	Ritu Saxena, MD*	23, 24	She was on the Steering Committee of the International Stroke Trial. The IST sponsors included the UK Stroke Foundation which is funded by Astra Zeneca, Boehringer, Bristol-Myers-Squibb, Ingleheim, Sanofi-Synthelabo, Merck Sharp Dohme, and Pfizer. ^{2, 15}
30	Holger J. Schünemann, MD*	22	Dr. Schünemann has received research funding from AstraZeneca, Boehringer Ingelheim, Pfizer, and Amgen Inc. He has received honoraria and consultant fees from AstraZeneca, Boehringer Ingelheim, and Amgen that were deposited into research accounts at the University of Buffalo and McMaster University. ⁴ He was co-author of 6 articles from the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. ⁴¹⁻⁴⁶ AstraZeneca LP; Aventis Pharmaceuticals; Bristol-Myers Squibb/Sanofi-Synthelabo Partnership; GlaxoSmithKline; Organon Sanofi-Synthelabo LLC supported this anticoagulant-guideline producing conference. ⁴
31	W. Sevcik, MD	30	His employer, the Division of Emergency Medicine, University of Alberta, received funding from Pharmacia,

			Aventis, and Sanofi for educational and research purposes. ³⁸
32	Prakesh Shah, MD*	40, 41, 48, 49	After concluding review #48 of continuous heparin infusion to prolong CVP catheter use in neonates, the authors initiated an RCT evaluating this intervention supported by the SickKids Foundation/Institute for Human Development, Child and Youth Health—CIHR National Grants Program. ⁴⁷ Baxter Corporation, Bayer Inc. and GlaxoSmithKline are financial supporters of The SickKids Foundation/Institute for Human Development. ⁴⁸
33	Vibhuti Shah, MD*	40, 41	Dr. Shah is a co-author of an RCT evaluating continuous heparin infusion to prolong CVP catheter use in neonates supported by the SickKids Foundation/Institute for Human Development, Child and Youth Health—CIHR National Grants Program. ⁴⁷ Baxter Corporation, Bayer Inc. and GlaxoSmithKline are financial supporters of The SickKids Foundation/Institute for Human Development. ⁴⁸
34	Jan Stam, MD*	1	He was co-principal investigator for the cerebral venous sinus thrombosis (CVST) trial. Sanofi-Winthrop (Dutch division) funded the trial.
35	Peer Wille-Jørgensen, MD*	28	He has received research funding from Novartis ⁴⁹ and co-authored a Pfizer-funded dalteparin prophylaxis trial. ⁴⁰
36	J. van Gijn, MD*	33	He/she is a member of the Executive Committee of ESPRIT, the European / Australian Stroke Prevention in Reversible Ischaemia Trial. ²¹ The UK Stroke Association contributed to the ESPRIT trial. ⁵⁰ The UK Stroke Association sponsors include Boehringer Ingelheim,

			Sanofi-Synthelabo, Bristol Myers Squibb, Pfizer, Merck Sharp Dohme, and Astra Zeneca. ²
--	--	--	---

* Undisclosed financial conflict of interest

1. Sandercock P, Algra A, Anderson C, P Bath, D Berezcki, E Berge, A Bowen, L Candelise, A Forster, H Fraser, G Hankey, P Langhorne, S Lewis, M Liu, A McInnes, K Prasad, C Sudlow, Thomas. B: **Cochrane Stroke Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2005, Issue 2. Art. No.: STROKE.**
2. UK Stroke Association. Available at: http://www.stroke.org.uk/fundraising/company_support/corporate_2.html. Accessed January 17, 2007.
3. O'Donnell MJ, Berge E, Sandset PM: **Are there patients with acute ischemic stroke and atrial fibrillation that benefit from low molecular weight heparin?** *Stroke* 2006, **37**(2):452-455.
4. **Financial Disclosures.** *Chest*, **126**(3_suppl):167S-171.
http://www.chestjournal.org/cgi/content/full/126/163_suppl/167S.
http://www.chestjournal.org/cgi/content/full/126/3_suppl/167S
5. Cassar K, Ford I, Greaves M, Bachoo P, Brittenden J: **Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination versus aspirin alone after lower limb angioplasty.** *Br J Surg* 2005, **92**(2):159-165.
6. Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J: **Variability in responsiveness to clopidogrel in patients with intermittent claudication.** *Eur J Vasc Endovasc Surg* 2006, **32**(1):71-75.
7. Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J: **Clopidogrel has no effect on D-dimer and thrombin-antithrombin III levels in patients with peripheral arterial disease undergoing peripheral percutaneous transluminal angioplasty.** *Journal of Vascular Surgery* 2005, **42**(2):252-258.
8. Hirsch AT, Criqui MH, Hiatt WR, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM: **Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care.** **10.1001/jama.286.11.1317.** *JAMA*, **286**(11):1317-1324. <http://jama.ama-assn.org/cgi/content/abstract/286/11/1317>
9. (NDA) 20-287 S-035: FRAGMIN® (dalteparin sodium). *Oncologic Drugs Advisory Committee Meeting.* <http://www.fda.gov/ohrms/dockets/ac/06/waivers/2006-4235W1-08-Hiatt-208.pdf>. Hilton Washington DC/Silver Spring: Pfizer, Incorporated.
10. **The Matisse Investigators. Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism.** *N Engl J Med* 2003, **349**(18):1695-1702. <http://content.nejm.org/cgi/content/full/349/18/1695>
11. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AEM, Cariou R, Leeuwenkamp O, Lensing AWA: **Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis: A Randomized Trial.** *Ann Intern Med* 2004, **140**(11):867-873 <http://www.annals.org/cgi/reprint/140/811/867.pdf>.
<http://www.annals.org/cgi/content/abstract/140/11/867>

12. Sanofi-Synthelabo to Sell to GlaxoSmithKline Arixtra(R), Fraxiparine(R) and Notre Dame de Bondeville Plant. *PRNewswire-FirstCall*. April 13, 2004. Accessed July 29, 2006.
13. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE: **Antithrombotic Therapy for Venous Thromboembolic Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy**. *Chest*, **126**(3_suppl):401S-428. C:\Documents and Settings\David K. Cundiff\My Documents\Whistle\DVT\Chest AC Guidelines 9-04\Antithrombotic Rx for VTE Buller.htm
14. Koopman MM, Prandoni P, Prins MH, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, Gallus AS, Simonneau G, Chesterman CH: **Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group**. *New England Journal of Medicine* 1996, **334**(11):682-687.
15. Saxena R, Lewis S, Berge E, Sandercock PAG, Koudstaal PJ: **Risk of Early Death and Recurrent Stroke and Effect of Heparin in 3169 Patients With Acute Ischemic Stroke and Atrial Fibrillation in the International Stroke Trial**. **10.1161/hs1001.097093**. *Stroke*, **32**(10):2333-2337. <http://stroke.ahajournals.org/cgi/content/abstract/32/10/2333>
16. Sandercock P, Mielke O, Liu M, Counsell C: **Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack**. *Cochrane Database of Systematic Reviews* 2003, (Issue 1):Art. No.: CD000248. DOI: 000210.001002/14651858.CD14000248. Abstract available at: <http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD14000248/frame.html>
Feedback letter: <http://doctormanagedcare.com/Sandercock14651852.htm> or <http://www.cochranefeedback.com/cf/cda/feedback.do?DOI=14651810.14651002/14651858.CD14000248&reviewGroup=HM-STROKE>.
17. Stein PD, Fowler SE, Goodman LR, Gottschalk A, Hales CA, Hull RD, Leeper KV, Jr., Popovich J, Jr., Quinn DA, Sos TA, Sostman HD, Tapson VF, Wakefield TW, Weg JG, Woodard PK, the PIOPED II Investigators: **Multidetector Computed Tomography for Acute Pulmonary Embolism**. **10.1056/NEJMoa052367**. *N Engl J Med*, **354**(22):2317-2327. <http://content.nejm.org/cgi/content/abstract/354/22/2317>
18. Vascular Surgery: Conrad Jobst Vascular Surgery Research Laboratory. *University of Michigan Medical Center*. Available at: <http://www.um-surgery.org/research/prospectus/vascular.shtml>. Accessed June 19, 2007.
19. McLafferty RB, Lohr JM, Wakefield TW, Caprini JA, Passman MA, Padberg FT, Rooke TW, Bush RL, Zakaria AA, Flinn WR, Eklof BG, Dalsing MC, Markwell SJ: **Results of the national pilot screening program for venous disease by the American Venous Forum**. *J Vasc Surg*. 2007, **45**(1):142-148.
20. De Schryver ELLM: **Dipyridamole in Stroke Prevention: Effect of Dipyridamole on Blood Pressure**. **10.1161/01.STR.0000090346.45784.C3**. *Stroke*, **34**(10):2339-2342. <http://stroke.ahajournals.org/cgi/content/abstract/34/10/2339>
21. The ESPRIT Study Group, Algra A: **Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial**. *Lancet Neurol*. 2007, **6**(2):115-124.
22. Planes A, Samama MM, Lensing AW, Buller HR, Barre J, Vochelle N, Beau B: **Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin**. *Thromb Haemost* 1999, **81**(1):22-25.

23. Cleland JG: **Chronic Aspirin Therapy for the Prevention of Cardiovascular Events: A Waste of Time, or Worse?** *Nature Clinical Practice Cardiovascular Medicine*, 3(5):234-235.
24. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M: **Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.** PEGASUS investigators. *Br J Surg*. 2005, 92(10):1212-1220.
25. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AGG, Egberts JFM, Lensing AWA, ARTEMIS Investigators: **Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.** 10.1136/bmj.38733.466748.7C. *BMJ* February 11, 2006, 332(7537):325-329. <http://bmj.bmjournals.com/cgi/content/full/332/7537/325>
26. **A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE Investigators).** *Lancet* 1996, 348:1329-1339.
27. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AWA, Tripodi A, the PROLONG Investigators: **D-Dimer Testing to Determine the Duration of Anticoagulation Therapy.** 10.1056/NEJMoa054444. *N Engl J Med* October 26, 2006, 355(17):1780-1789. <http://content.nejm.org/cgi/content/abstract/355/17/1780>
28. de Bruijn SFTM, Stam J: **Randomized, Placebo-Controlled Trial of Anticoagulant Treatment With Low-Molecular-Weight Heparin for Cerebral Sinus Thrombosis.** *Stroke*, 30(3):484-488. <http://stroke.ahajournals.org/cgi/content/abstract/30/3/484>
29. The Heart and Stroke Foundation of Canada. Available at: <http://ww2.heartandstroke.ca/Page.asp?PageID=1366&ArticleID=4803&Src=blank&From=SubCategory> and http://ww2.heartandstroke.ca/images/english/HSFCAR05_Engweb.pdf. Accessed January 17, 2007.
30. Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S: **Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials.** 0.1161/CIRCULATIONAHA.105.573550. *Circulation* December 20, 2005, 112(25):3855-3867. <http://circ.ahajournals.org/cgi/content/abstract/112/25/3855>
31. Quinlan DJ, McQuillan A, Eikelboom JW: **Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism: A Meta-Analysis of Randomized, Controlled Trials.** *Ann Intern Med* 2004, 140(3):175-183. <http://www.annals.org/cgi/content/abstract/140/3/175>
32. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BSP, Petersen P: **Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin.** 10.1161/01.CIR.0000145172.55640.93. *Circulation*, 110(16):2287-2292. <http://circ.ahajournals.org/cgi/content/abstract/110/16/2287>
33. American Heart Association Annual Report. *AHA*. Available at: http://www.americanheart.org/downloadable/heart/1165958761497AHA%20AR%202006_FIN_AL.pdf. Accessed January 10, 2007.
34. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, S. Y, ACTIVE Writing Group of the ACTIVE Investigators: **Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.** *Lancet* 2006, 367(9526):1903-1912.

35. Hamulyak K, Lensing AW, van der Meer J, Smid WM, van Ooy A, Hoek JA: **Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group.** *Thromb Haemost* 1995, **74**(6):1428-1431.
36. Kamath S, Blann AD, Chin BS, Lip GY: **A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation.** *J Am Coll Cardiol* 2002, **40**(3):484-490.
37. Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV: **Effects of a Low-Molecular-Weight Heparin on Thrombus Regression of Recurrent Thromboembolism in Patients with Deep-Vein Thrombosis. The CORTES Investigators.** *New England Journal of Medicine* 2001, **344**(9):626-631.
38. Magee KD, Sevcik W, Moher D, Rowe BH: **Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes.** *Cochrane Database Syst Rev* 2003, (1):Art No. CD002132. Abstract available at:
<http://www.mrw.interscience.wiley.com/cochrane/clsystrev/articles/CD002132/frame.html>
Feedback letter: <http://doctormanagedcare.com/Magee002132.htm> or
<http://www.cochranefeedback.com/cf/cda/feedback.do?DOI=002110.001002/14651858.CD14002132&reviewGroup=HM-HEART> or
<http://www.cochranefeedback.com/cf/cda/citation.do?id=14659697#14659697>.
39. Wille-Jørgensen P, Rasmussen M, Andersen B, Borly L: **Heparins and mechanical methods for thromboprophylaxis in colorectal surgery.** *Cochrane Database of Systematic Reviews* 2004, (Issue 1):Art. No.: CD001217 DOI: 001210.001002/14651858.CD14001217. Abstract available at:
<http://www.mrw.interscience.wiley.com/cochrane/clsystrev/articles/CD14001217/frame.html>
Feedback letter: <http://doctormanagedcare.com/WilleJorgensen.htm> or
<http://www.cochranefeedback.com/cf/cda/feedback.do?DOI=14651810.14651002/14651858.CD14001217&reviewGroup=HM-PVD>.
40. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, Nielsen JD, Horn A, Mohn AC, Somod L, Olsen B, Investigators. obotF: **Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study.** *J Thromb Haemost* 2006, **4**(11):2384-2390.
41. Stein PD, Schunemann HJ, Dalen JE, Gutterman D: **Antithrombotic Therapy in Patients With Saphenous Vein and Internal Mammary Artery Bypass Grafts: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.** *Chest*, **126**(3_suppl):600S-608. C:\Documents and Settings\David K. Cundiff\My Documents\Whistle\DVT\Chest AC Guidelines 9-04\AC with CABG Stein.htm
42. Schunemann HJ, Cook D, Grimshaw J, Liberati A, Heffner J, Tapson V, Guyatt G: **Antithrombotic and Thrombolytic Therapy: From Evidence to Application: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.** *Chest*, **126**(3_suppl):688S-696. C:\Documents and Settings\David K. Cundiff\My Documents\Whistle\DVT\Chest AC Guidelines 9-04\AC and Thrombolysis evidence to applic Schunemann.htm
43. Schunemann HJ, Munger H, Brower S, O'Donnell M, Crowther M, Cook D, Guyatt G: **Methodology for Guideline Development for the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.** *Chest*, **126**(3_suppl):174S-178.

44. Menon V, Harrington RA, Hochman JS, Cannon CP, Goodman SD, Wilcox RG, Schunemann HJ, Ohman EM: **Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.** *Chest* 2004, **126**(3_suppl):549S-575. C:\Documents and Settings\David K. Cundiff\My Documents\Whistle\DVT\Chest AC Guidelines 9-04\Thrombolysis in AMI Menon.htm
45. Hirsh J, Guyatt G, Albers GW, Schunemann HJ: **The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines.** *Chest*, **126**(3_suppl):172S-173. http://www.chestjournal.org/cgi/reprint/126/3_suppl/172S

C:\Documents and Settings\David K. Cundiff\My Documents\Whistle\DVT\Chest AC Guidelines 9-04\Evidence-based Guidelines.htm

46. Guyatt G, Schunemann HJ, Cook D, Jaeschke R, Pauker S: **Applying the Grades of Recommendation for Antithrombotic and Thrombolytic Therapy: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.** *Chest*, **126**(3_suppl):179S-187. C:\Documents and Settings\David K. Cundiff\My Documents\Whistle\DVT\Chest AC Guidelines 9-04\Applying Grades of Recs Guyatt.htm
47. Shah PS, Kalyn A, Satodia P, Dunn MS, Parvez B, Daneman A, Salem S, Glanc P, Ohlsson A, Shah V: **A Randomized, Controlled Trial of Heparin Versus Placebo Infusion to Prolong the Usability of Peripherally Placed Percutaneous Central Venous Catheters (PCVCs) in Neonates: The HIP (Heparin Infusion for PCVC) Study. 10.1542/peds.2006-0529.** *Pediatrics*, **119**(1):e284-291. <http://pediatrics.aappublications.org/cgi/content/full/119/1/e284>
48. Corporate Partnerships - Our Corporate Partners. *Sick Kids Foundation*. 2007. Available at: <http://sickkidsfoundation.com/Corporate/partners.asp>. Accessed August 11, 2007.
49. Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, Baur M, Ekman S, Bach D, Lindbratt S, Close P: **A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.** *N Eng J Med* 1997, **337**(19):1329-1335.
50. ESPRIT: **Oral Anticoagulation in Patients After Cerebral Ischemia of Arterial Origin and Risk of Intracranial Hemorrhage.** *Stroke*, **34**(6):45e-46. <http://stroke.ahajournals.org/cgi/content/abstract/34/6/e45>